Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.

Gefurulimab met all primary and secondary endpoints in the Phase III PREVAIL trial in patients with gMG, run by pharma giant AstraZeneca.

Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Iran dropped down to third for trial initiations outside of North America and Europe. Image credit: TarikVision / Shutterstock.com Escalating conflict between Israel, Iran and the US had a marked ...

Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Diakonos Oncology has dosed the first subject in its Phase II trial of DOC1021 for treating glioblastoma (GBM).

Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin in preventing AKI.

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.